How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,313 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Aortic dissection with concomitant acute myocardial infarction: From diagnosis to management Full Text available with Trip Pro

Aortic dissection with concomitant acute myocardial infarction: From diagnosis to management Acute aortic dissection an extremely severe condition having a high risk of mortality. The classic symptom may mimic other conditions such as myocardial ischemia, leading to misdiagnosis. Coronary malperfusion associated with aortic dissection is relatively rare, but when it occurs, it may have a fatal result for the patient. The diagnosis of acute coronary syndrome may lead to the inappropriate (...) administration of thrombolytic or anticoagulant treatment resulting in catastrophic consequences. Emergency imaging techniques help to guide the correct diagnosis. Transthoracic echocardiography is useful as a first imaging test, and may be followed by transesophageal echocardiography, or other imaging techniques. Surgery represents the treatment for these patients. However, with the aim to stabilize the patient and to reduce myocardial damage, initial preoperative endovascular coronary intervention has been

2011 Journal of Emergencies, Trauma and Shock

202. Biomaterial strategies for alleviation of myocardial infarction Full Text available with Trip Pro

Biomaterial strategies for alleviation of myocardial infarction World Health Organization estimated that heart failure initiated by coronary artery disease and myocardial infarction (MI) leads to 29 per cent of deaths worldwide. Heart failure is one of the leading causes of death in industrialized countries and is expected to become a global epidemic within the twenty-first century. MI, the main cause of heart failure, leads to a loss of cardiac tissue impairment of left ventricular function (...) . The damaged left ventricle undergoes progressive 'remodelling' and chamber dilation, with myocyte slippage and fibroblast proliferation. Repair of diseased myocardium with in vitro-engineered cardiac muscle patch/injectable biopolymers with cells may become a viable option for heart failure patients. These events reflect an apparent lack of effective intrinsic mechanism for myocardial repair and regeneration. Motivated by the desire to develop minimally invasive procedures, the last 10 years observed

2011 Journal of the Royal Society Interface

203. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction Full Text available with Trip Pro

Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction Cardiac myosin binding protein-C (cMyBP-C) is a thick filament assembly protein that stabilizes sarcomeric structure and regulates cardiac function; however, the profile of cMyBP-C degradation after myocardial infarction (MI) is unknown. We hypothesized that cMyBP-C is sensitive to proteolysis and is specifically increased in the bloodstream post-MI in rats and humans. Under these circumstances (...) the proteolytic pattern of cMyBP-C post-MI, the left anterior descending coronary artery was ligated in adult male rats. Degradation of cMyBP-C was confirmed by a reduction in total cMyBP-C and the presence of degradation products in the infarct tissue. Phosphorylation levels of cMyBP-C were greatly reduced in ischemic areas of the MI heart compared to non-ischemic regions and sham control hearts. Post-MI plasma samples from these rats, as well as humans, were assayed for cMyBP-C and its fragments by sandwich

2011 Journal of Molecular and Cellular Cardiology

204. Importance of Suitable Reference Gene Selection for Quantitative Real-Time PCR: Special Reference to Mouse Myocardial Infarction Studies Full Text available with Trip Pro

Importance of Suitable Reference Gene Selection for Quantitative Real-Time PCR: Special Reference to Mouse Myocardial Infarction Studies Quantitative real-time PCR (qPCR) is a widely used technique for gene expression analysis. Its reliability is highly dependent upon selection of the appropriate reference genes for accurate gene expression normalization. In this study, we investigated the expression stability of 10 commonly used reference genes in a mouse myocardial infarction model.The (...) expression stability of the 10 reference genes (Actb, B2m, Eef1a1, Gapdh, Hprt, Polr2a, Ppia, Rpl13a, Tbp, Tpt1) was analyzed using the geNorm software. Overall, the combination of Hprt, Rpl13a and Tpt1 was the most stable reference gene set in our experiments. Gapdh, Polr2a and Actb consistently showed the highest gene expression variability and the expression levels of Gapdh, Polr2a, Actb, B2m and Eef1a1 were found to be selectively up- or downregulated after myocardial infarction. We normalized

2011 PloS one

205. Frequency and Healing of Nonculprit Coronary Artery Plaque Disruptions in Patients With Acute Myocardial Infarction. (Abstract)

Frequency and Healing of Nonculprit Coronary Artery Plaque Disruptions in Patients With Acute Myocardial Infarction. The pathophysiology of plaque disruption and healing in nonculprit segments has not been clarified. Therefore, we investigated the frequency of plaque disruptions in nonculprit segments and whether those plaques are stabilized during follow-ups in patients with acute myocardial infarction (AMI) by serial angioscopic observations. Analyzed were 13 consecutive patients with AMI (...) in whom infarct-related arteries were serially observed by angioscopy immediately after reperfusion and at 1- and 6-month follow-ups. Color of plaques was graded as 0 (white), 1 (slight yellow), 2 (yellow), or 3 (intensive yellow). Plaques with thrombus were defined as disrupted. Although number of nonculprit yellow plaques did not change from immediately after reperfusion to 6 months, the maximum color grade of those plaques and incidence of disrupted plaques in nonculprit segments (immediate vs 1

2011 American Journal of Cardiology

206. Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. Full Text available with Trip Pro

Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. In patients with cardiogenic shock (CS) complicating an acute myocardial infarction, a strategy of early revascularization (ERV) versus initial medical stabilization (IMS) improves survival. Intra-aortic balloon counterpulsation (IABC) provides hemodynamic support and facilitates coronary angiography

2011 American heart journal Controlled trial quality: uncertain

207. Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.

Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction. Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction. (OCTIVUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01385631 Recruitment Status : Completed First

2011 Clinical Trials

208. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR (Abstract)

Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR Adiponectin, an adipocytokine, is secreted by fatty cells and exerts a regulatory role in atherogenesis, modulating foam cell formation and cellular adhesion. In stable atherosclerosis, plasma adiponectin has been reported to be associated (...) regression, we adjusted for age, sex, race, ACS type, diabetes, smoking status, triglycerides, blood pressure, body mass index, estimated glomerular filtration rate, treatment group (atorvastatin), B-type natriuretic peptide, and C-reactive protein.Adiponectin correlated negatively with age, diabetes, body mass index, and triglycerides (each, P < .001) but showed a positive relationship with the risk of death (P = .01), myocardial infarction (P = .01), and heart failure (P < .001). After adjusting

2011 American heart journal Controlled trial quality: uncertain

209. Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: - suspected CAD for which an indication to PCI is given: both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e (...) ., with variations <20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction). Exclusion Criteria: any previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline; history of liver toxicity or myopathy on previous treatment with statins; left ventricular ejection fraction <30%; renal insufficiency, with creatinine >2 mg/dL at baseline; ongoing treatment with high-dose statins

2014 Clinical Trials

210. Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)

A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the 60 days prior to randomization Revascularization within 60 days prior to randomization Inability to walk on a treadmill except for class IV angina patients who will be evaluated separately Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal range (x ULN) Hemoglobin ≤ 10.0 g/dL Contacts and Locations Go to Information from the National (...) Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

211. Myocardial delayed enhancement with dual-source CT: advantages of targeted spatial frequency filtration and image averaging over half-scan reconstruction. (Abstract)

Myocardial delayed enhancement with dual-source CT: advantages of targeted spatial frequency filtration and image averaging over half-scan reconstruction. Clinical utility of myocardial delayed-enhancement CT is currently limited because of relatively poor contrast-to-noise ratio (CNR) and artifacts. Targeted spatial-frequency filtration (TSFF) is a hybrid algorithm of half- and full-scan reconstruction that can achieve both high temporal resolution and improved stability of myocardial (...) signal.The purpose of this study was to evaluate image quality of delayed-enhancement CT using TSFF with image averaging and its reproducibility in infarct assessment in comparison with conventional half-scan reconstruction (HALF).Forty patients with suspected coronary artery disease underwent delayed-enhancement CT with HALF and TSFF using dual-source CT. Two blinded readers independently determined the presence and size of delayed enhancement. Image quality, signal-to-noise ratio and CNR were assessed

2014 Journal of cardiovascular computed tomography

212. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Heart Association (NYHA) criteria, or myocardial infarction within 6 months Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2012 Clinical Trials

213. Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer

requiring staging) must be performed within 35 days prior to the start of therapy No serious medical conditions such as myocardial infarction within 6 months prior to entry, congestive heart failure, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, psychiatric illness, or any other medical conditions that might be aggravated by treatment or limit compliance Currently, no active (...) Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2012 Clinical Trials

214. A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASCâ„¢) Device

Device Device: Apica Cardiovascular ASC Access, Stability and Closure Device Access, stabilisation and closure of trans-apical approach for TAVI Other Name: Apica Cardiovascular, ASC Outcome Measures Go to Primary Outcome Measures : Access safety [ Time Frame: Within 2 hours from initial skin incision ] Observation of no myocardial tearing on entry of the device Closure safety [ Time Frame: Within 2 hours from initial skin incision ] Observation of no acute post-procedural bleeding or pericardial (...) or serious, irreversible morbidity exceeded 50%. Exclusion Criteria: Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. The following TAVI exclusion criteria shall apply: Evidence of an acute myocardial infarction < 1 month before the intended treatment Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant

2012 Clinical Trials

215. Myocardial infarction Full Text available with Trip Pro

Myocardial infarction Myocardial infarction - Wikipedia Myocardial infarction From Wikipedia, the free encyclopedia "Heart attack" redirects here. For other uses, see . Myocardial infarction Other names Acute myocardial infarction (AMI), heart attack Diagram showing the by the two major blood vessels, the and (labelled LCA and RCA). A myocardial infarction (2) has occurred with blockage of a branch of the left coronary artery (1). , Symptoms , , nausea, , , ; arm, neck, back, jaw, or stomach (...) pain , , , Causes Usually , , , , , (ECGs), blood tests, Treatment , Medication , , Prognosis STEMI 10% risk of death (developed world) Frequency 15.9 million (2015) Myocardial infarction ( MI ), commonly known as a heart attack , occurs when decreases or stops to a part of the , causing damage to the . The most common symptom is or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes

2012 Wikipedia

216. Myocardial Rupture (Treatment)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

217. Myocardial Abscess (Treatment)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

218. Myocardial Ischemia (Treatment)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

219. Myocardial Rupture (Follow-up)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

220. Myocardial Abscess (Follow-up)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>